# Research Loop Progress

## Current Session: h250, h255, h258 (2026-02-05)

### Session Summary

**Agent Role:** Research Executor
**Status:** Complete
**Hypotheses Tested: 3**
- h250: Systematic Drug Class Safety Review for Cardiovascular - **VALIDATED**
- h255: Antiarrhythmic Safety Review Beyond Class Ic - **VALIDATED**
- h258: Inverse Indication Pattern Detection - **VALIDATED**

### Cumulative Statistics (2026-02-05)
| Status | Count |
|--------|-------|
| Validated | 145 |
| Invalidated | 50 |
| Inconclusive | 8 |
| Blocked | 18 |
| Deprioritized | 3 |
| Pending | 34 |
| **Total** | **258** |

### Session Theme: Safety Filter Enhancement

**h250: CV Drug Class Safety Review**
- Added 4 contraindication categories (non-DHP CCBs, Class Ic antiarrhythmics, ganglionic blockers, surgical dyes)
- 91 predictions excluded (9 HIGH tier)
- Evidence: ACC/AHA guidelines, CAST trial, PROMISE trial

**h255: Antiarrhythmic Safety Review**
- Added 4 more rules (dronedarone+HF, sotalol+MI, Class Ia+MI, procainamide iatrogenic)
- 5 predictions excluded
- Evidence: ANDROMEDA trial, SWORD trial, TdP literature
- Key finding: Procainamide→agranulocytosis is "inverse indication" (drug CAUSES condition)

**h258: Inverse Indication Pattern Detection**
- Systematic search for drugs predicted to treat conditions they cause
- Added: Amiodarone→thyroid, NSAIDs→peptic ulcer
- 2 additional predictions excluded
- **Total inverse indication exclusions: 5**

### Safety Filters Added This Session

| Rule | Drug Class | Condition | Evidence |
|------|------------|-----------|----------|
| h250 | Non-DHP CCBs | Heart Failure | ACC/AHA 2022 |
| h250 | Class Ic antiarrhythmics | Structural heart | CAST trial |
| h250 | Ganglionic blockers | Any | Obsolete |
| h250 | Surgical dyes | Any | Not therapeutic |
| h255 | Dronedarone | Heart failure | ANDROMEDA trial |
| h255 | Sotalol | Post-MI | SWORD trial |
| h255 | Class Ia | Post-MI | TdP literature |
| h255 | Procainamide | Agranulocytosis/lupus | Iatrogenic |
| h258 | Amiodarone | Thyroid dysfunction | 14-18% incidence |
| h258 | NSAIDs | Peptic ulcer | COX-1 inhibition |

### Session Impact Summary

**New predictions excluded: 98**
- h250: 91 (9 HIGH tier)
- h255: 5 (0 HIGH tier)
- h258: 2 (0 HIGH tier)

**Total filter coverage: 307 predictions (2.3%)**

### Key Learning: Inverse Indication Pattern

Drugs can be predicted to treat conditions they actually CAUSE when:
1. Both "causes" and "treats" create similar graph patterns
2. Drug-disease associations in knowledge graphs don't distinguish direction
3. Examples: Procainamide→agranulocytosis, Amiodarone→thyroid, NSAIDs→ulcers

**Solution:** Maintain adverse effect database, cross-reference all predictions.

### Recommended Next Steps (Priority Order)
1. **h96**: PPI-Extended Drug Targets (medium effort)
2. **h91**: Literature Mining for zero-treatment diseases (high effort, high impact)
3. **h159**: Category Boundary Refinement (low effort)

---

## Previous Sessions

### 2026-02-05 (Earlier): h244, h248, h251, h249, h253, h252
- SGLT2 inhibitors: 63.9% precision (BEST drug class)
- PAH drug safety filters: 23.3% of HF predictions were HARMFUL
- sGC stimulators: Teratogenic - pregnancy filter added

See git history for detailed session notes.

---

## Archive

See previous entries in git history.
